Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Source of water, electrolytes, and calories for parenteral nutrition,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis (via acetate/gluconate)
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Dextrose: <15 minutes (rapidly cleared from plasma); Electrolytes: No true half-life, as they are distributed and excreted according to homeostatic mechanisms.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, providing energy. Acetate and gluconate are metabolized primarily in the liver and skeletal muscle to bicarbonate. Electrolytes are not metabolized.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal: 90% (as water and electrolytes); Dextrose is metabolized to CO2 and water, with negligible renal excretion of unchanged drug.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Minimal (<5%) for electrolytes and dextrose; not significantly bound to plasma proteins.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Electrolytes: Vd of sodium ~0.6 L/kg (total body water); Dextrose: Vd ~0.2-0.3 L/kg (extracellular fluid); overall Vd approximates 0.6 L/kg.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Not applicable; drug is only administered intravenously (IV), so bioavailability is 100%.
100% intravenous; not administered by other routes.
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to risk of potassium and magnesium accumulation; for e GFR 30-59 m L/min/1.73 m², reduce infusion rate by 50% and monitor electrolytes; no adjustment for e GFR ≥ 60 m L/min/1.73 m².
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Child-Pugh Class A or B: no adjustment needed; Child-Pugh Class C: monitor serum magnesium and potassium closely due to reduced clearance; consider reduced infusion rate (e.g., 75% of normal) and frequent electrolyte monitoring.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion; dose based on weight: infants: 100-150 m L/kg/day; children: 100-200 m L/kg/day; adjust for ongoing losses and serum glucose; not recommended for neonates due to risk of hyperkalemia; maximum infusion rate 2-5 m L/kg/hour depending on age and clinical status.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Elderly patients: use lower initial rates (e.g., 50-100 m L/hour) with careful monitoring of fluid overload, serum electrolytes, and glucose tolerance; due to age-related renal decline, consider dose reduction if e GFR < 60 m L/min/1.73 m²; avoid in patients with heart failure or significant renal impairment.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component.
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload.,Monitor serum glucose, electrolytes, and fluid status regularly.,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis.,Do not administer simultaneously with blood through the same infusion set (risk of hemolysis) unless using a Y-type connector with proper flushing.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Severe hyperglycemia (e.g., diabetic ketoacidosis),Hyperkalemia,Severe renal impairment with oliguria or anuria,Hypersensitivity to any component
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions. Dietary potassium/magnesium intake should be monitored in patients receiving this solution to avoid electrolyte imbalance. Patients with diabetes should coordinate dextrose infusion with insulin and meal timing.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is negligible as the solution is designed to replace fluids and electrolytes. No teratogenic effects reported in animal studies or human data. Trimester-independent low risk, but use only if clearly needed.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Compatible with breastfeeding. Components (dextrose, electrolytes) are endogenous and present in breast milk. No known M/P ratio available as the solution is composed of substances normally present in milk. Excretion is not clinically relevant; no adverse effects expected.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustments required. Pregnancy induces increased plasma volume (40-50%) and glomerular filtration rate (50-85%), but crystalloid solutions like Plasma-Lyte M and Dextrose 5% are dosed based on clinical need (fluid replacement, maintenance). Monitor for hyperglycemia due to dextrose; consider lower infusion rates in gestational diabetes or preeclampsia-related fluid sensitivity.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
PLASMA-LYTE M AND DEXTROSE 5% is a balanced isotonic crystalloid containing multiple electrolytes (Na 40, K 13, Mg 3, Cl 40, acetate 16, gluconate 20 m Eq/L) with 5% dextrose. It is used for maintenance fluid therapy, particularly in pediatric or geriatric patients, or when mild potassium/magnesium supplementation is needed. The dextrose provides ~170 kcal/L and helps prevent ketosis. Avoid in patients with hyperkalemia, hypermagnesemia, or anuria. Acetate and gluconate serve as bicarbonate precursors (acetate is rapidly metabolized; gluconate slower). Monitor serum glucose in diabetics or stress states. Compatible with most IV medications; check specific compatibility.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This intravenous solution contains sugar (dextrose) and electrolytes to maintain fluid balance and provide calories.,Tell your healthcare provider if you have diabetes, kidney problems, or heart disease.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,This solution may be given with other medications; inform your nurse of all medications you are taking.,You may experience a cold sensation at the IV site; this is usually temporary.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is neg. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.